Astria Therapeutics Q4 EPS $(0.86) Down From $(0.72) YoY
Portfolio Pulse from Happy Mohamed
Astria Therapeutics (NASDAQ:ATXS) reported a Q4 EPS loss of $(0.86), marking a 19.44% increase in losses compared to $(0.72) per share from the same period last year.
March 04, 2024 | 9:20 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Astria Therapeutics reported increased quarterly losses, which may concern investors about the company's financial health.
The reported increase in losses for Astria Therapeutics is likely to negatively impact investor sentiment in the short term, as it indicates a worsening financial condition compared to the previous year.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100